Ixabepilone Patent Expiration
Ixabepilone is Used for treating cancer, specifically breast cancer, by administering Ixabepilone in various formulations and regimens including intravenous administration and combination therapy with Capecitabine. It was first introduced by R-Pharm Us Llc
Ixabepilone Patents
Given below is the list of patents protecting Ixabepilone, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Ixempra Kit | US6670384 | Methods of administering epothilone analogs for the treatment of cancer |
Jan 23, 2022
(Expired) | R-pharm Us Llc |
| Ixempra Kit |
US6670384 (Pediatric) | Methods of administering epothilone analogs for the treatment of cancer |
Jul 23, 2022
(Expired) | R-pharm Us Llc |
| Ixempra Kit | US7022330 | Parenteral formulation for epothilone analogs |
Jan 23, 2022
(Expired) | R-pharm Us Llc |
| Ixempra Kit |
US7022330 (Pediatric) | Parenteral formulation for epothilone analogs |
Jul 23, 2022
(Expired) | R-pharm Us Llc |
| Ixempra Kit | US7125899 | Epothilone derivatives |
May 26, 2018
(Expired) | R-pharm Us Llc |
| Ixempra Kit |
US7125899 (Pediatric) | Epothilone derivatives |
Nov 26, 2018
(Expired) | R-pharm Us Llc |
| Ixempra Kit | US7312237 | Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases | Aug 21, 2024 | R-pharm Us Llc |
| Ixempra Kit |
US7312237 (Pediatric) | Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases | Feb 21, 2025 | R-pharm Us Llc |
| Ixempra Kit | USRE41393 | Treatment of refractory tumors using epothilone derivatives |
Feb 08, 2022
(Expired) | R-pharm Us Llc |
| Ixempra Kit |
USRE41393 (Pediatric) | Treatment of refractory tumors using epothilone derivatives |
Aug 08, 2022
(Expired) | R-pharm Us Llc |
| Ixempra Kit | USRE41911 | Epothilone derivatives |
Sep 28, 2020
(Expired) | R-pharm Us Llc |
| Ixempra Kit |
USRE41911 (Pediatric) | Epothilone derivatives |
Mar 28, 2021
(Expired) | R-pharm Us Llc |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳